New drugs in the treatment of obesity: their availability for clinical practice

Authors: Ľubomíra Fábryová
Authors‘ workplace: Ambulancia diabetológie, porúch látkovej premeny a výživy, Metabol KLINIK s. r. o., Bratislava
Published in: Forum Diab 2016; 5(1): 29-34
Category: Topic


The first line in the treatment of obesity is a combination of a low calorie diet, increased physical activity and behavioral therapy. Unless these options fail, should be considered in an effective and safe pharmacotherapy. Antiobesitic market situation is changing, combination antiobesitic therapy enters into clinical practice. Currently in the US for long-term chronic treatment of obesity FDA approved five drugs: orlistat, lorcaserin, phentermine/topiramate ER, naltrexone SR / bupropion SR and liraglutide 3.0 mg. In the EU we have currently three approved drugs for chronic treatment of obesity: orlistat, naltrexone SR / bupropion SR and liraglutide 3.0 mg. However, the real availability of antiobesitic drugs is worldwide different. Differences in availability are as well as between countries of the European Union.

Key words:
lorcaserin – liraglutid 3.0 mg – naltrexon SR/bupropion SR – orlistat – phentermine/ topiramate ER


1. World Obesity Federation. Dostupné z WWW: <>.

2. Frühbeck G, Toplak H, Woodward E et al. Obesity: the gateway to ill health – an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts 2013; 6(2): 117–120.

3. Avdičová M, Francisciová K, Ďateľová M et al. Monitorovanie rizikových faktorov chronických chorôb v SR. Regionálny úrad verejného zdravotníctva so sídlom v Banskej Bystrici za podpory Svetovej zdravotníckej organizácie – regionálnej úradovne v Kodani, 2012. ISBN 978–80–971096–0-8.

4. Národné centrum zdravotníckych informácií. Štatistická ročenka 2012. Dostupné z WWW: <>.

5. Yumuk V, Frühbeck G, Oppert JM et al (for the Executive Committee of the European Association for the Study of Obesity). An EASO position statement on multidisciplinary obesity management in adults. Obes Facts 2014; 7(2): 96–101.

6. Fábryová Ľ. Farmakologická liečba obezity. In: Krahulec B, Fábryová Ľ, Holéczy P et al (eds). Klinická obezitológia. Facta Medica: Brno 2013: 132–144. ISBN 978–80–904731–7-1.

7. Fried M, Yumuk V, Oppert JM et al. Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery. Obes Facts 2013; 6(5): 449–468.

8. Toplak H, Woodward E, Yumuk V et al. 2014 EASO Position Statement on the Use of Anti-Obesity Drugs. Obes Facts 2015; 8(3): 166–174.

9. Fábryová Ľ. Weight loss pharmacotherapy of obese non-diabetic and type 2 diabetic patients. J Obes Weight Loss Ther 5: 277. Dostupné z DOI: <–7904.1000277>.

10. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311(1): 74–86.

11. McClendon K, Rich DM, Uwaifo GI. Orlistat: current status in clinical therapeutics. Expert Opin Drug Saf 2009; 8(6): 727–744.

12. Sjőstrőm L. Analysis of the XENDOS study (Xenical in the prevention of diabetes in obese subjects). Endocr Pract 2006; 12(Suppl 1): S31-S33.

13. Colman E, Golden J, Roberts M et al. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med 2012; 367(17):1577–1579.

14. Smith SR, O’Neil PM, Astrup A et al. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring) 2014; 22(10): 2137–2146.

15. Sweeting AN, Tabet E, Caterson ID et al. Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate. Diabetes Metab Syndr Obes 2014; 7: 35–44.

16. 16.Garvey WT. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf 2013; 12(5): 741–756.

17. Garvey WT, Ryan DH, Henry R et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care 2014; 37(4): 912–921.

18. Greenway FL, Fujioka K, Plodkowski RA et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376(9741): 595–605.

19. Apovian CM, AronneL, Rubino D et al. COR-II Study Group. A randomized, phase 3 trial of naltrexoneSR/bupropôion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring).2013:21:935–943. Erratum in Lancet 2010; 376(9750): 1392. Lancet 2010; 376(9741): 594.

20. Hollande P, Gupta AK, Plodkowski R et al. COR-Diabetes Study Group. Effects of naltrexone/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013: 36(12): 4022–4029. Erratum in Diabetes Care 2014; 37(2): 587.

21. Ornellas T, Chavez B. Naltrexone SR/Bupropion SR (Contrave) A New Approach to Weight Loss in Obese Adults. PT 2011; 36(5): 255–262.

22. Wadden TA, Foreyt JP, Foster GD et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR–BMOD Trial. Obesity (Silver Spring) 2011; 19(1): 110–120.

23. Verpeut JL, Bello NT. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf 2014; 13(6): 831–841.

24. Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity – GLP-1 and obesity. Expert Opin Pharmacother 2014; 15(17): 2487–2500.

25. Ng SY, Wilding JP. Liraglutide in the treatment of obesity. Expert Opin Biol Ther 2014; 14(8): 1215–1224.

26. Wadden T, Hollander P, Klein S et al (NN8022–1923 Investigators). Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013; 37(11): 1443–1451. Dostupné z DOI: <>. Erratum in Int J Obes (Lond) 2015; 39(1): 187. Int J Obes (Lond) 2013; 37(11): 1514.

27. Lorenz M, Evers A, Wagner M et al. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett 2013; 23(14): 4011–4018.

28. Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis 2014; 5(3): 135–148.

Diabetology Endocrinology Internal medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account